Page last updated: 2024-11-11

bn82002

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BN82002: inhibitor of CDC25 phosphatases; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9798923
CHEMBL ID1553873
SCHEMBL ID1917644
MeSH IDM0467931

Synonyms (25)

Synonym
HSCI1_000079
NCGC00165741-01
bn-82002
CHEMBL1553873
396073-89-5
unii-237srb7uqx
237srb7uqx ,
phenol, 4-(dimethylamino)-2-methoxy-6-((methyl(2-(4-nitrophenyl)ethyl)amino)methyl)-
SCHEMBL1917644
4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol
AS-58681
4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]-amino}methyl)phenol
GOKYHQGRIIXMNE-UHFFFAOYSA-N
EX-A2918
BCP29552
bn82002 pound>>bn-82002 pound>>cdc25 phosphatase inhibitor i, bn82002
bn82002
4-(dimethylamino)-2-methoxy-6-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenol
CS-0063820
HY-112776
bn82002 hydrochloride salt
cdc25 phosphatase inhibitor i
Q27253727
D93454
AKOS037515620

Research Excerpts

Overview

BN82002 is a original CDC25 inhibitor that is active both in cell and animal models.

ExcerptReferenceRelevance
"BN82002 is a original CDC25 inhibitor that is active both in cell and animal models."( A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Alby, F; Baldin, V; Brezak, MC; Cazales, M; Ducommun, B; Galcera, MO; Harnett, J; Kasprzyk, PG; Lanco, C; Lavergne, O; Mondésert, O; Prevost, GP; Quaranta, M; Thurieau, C, 2004
)
1.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.72210.003245.467312,589.2998AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency2.23870.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency7.92450.140911.194039.8107AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency53.37290.125919.1169125.8920AID2549; AID2708; AID504841
endonuclease IVEscherichia coliPotency0.63100.707912.432431.6228AID2565
phosphopantetheinyl transferaseBacillus subtilisPotency11.22020.141337.9142100.0000AID1490
Bloom syndrome protein isoform 1Homo sapiens (human)Potency14.12540.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency2.51190.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency25.11890.010039.53711,122.0200AID1469
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency2.99350.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency0.28180.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.28180.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency0.28180.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency0.28180.01418.602439.8107AID2572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID644236Inhibition of recombinant human GST-tagged cdc25A phosphatase activity using 3-O-methyl fluorescein phosphate at 100 uM2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells.
AID644235Inhibition of recombinant human GST-tagged cdc25C phosphatase activity using 3-O-methyl fluorescein phosphate at 100 uM2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.96 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]